{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:44:15Z","timestamp":1787021055774,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T00:00:00Z","timestamp":1699488000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T00:00:00Z","timestamp":1699488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100016471","name":"Agios Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016471","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pyruvate kinase (PK) deficiency is a rare hereditary disorder characterized by chronic hemolytic anemia and serious sequalae which negatively affect patient quality of life. This study aimed to psychometrically validate the first disease-specific patient-reported outcome (PRO) instruments: the 7-item PK Deficiency Diary (PKDD) and 12-item PK Deficiency Impact Assessment (PKDIA), designed to assess signs, symptoms, and impacts of PK deficiency in patients enrolled in the ACTIVATE global phase 3 study of mitapivat versus placebo (NCT03548220).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>All validation analyses for the PKDD and PKDIA were performed on blinded data, with analyses on item integrity, scoring, reliability, and validity conducted on data from screening and baseline. Completion rates and baseline response distributions were characterized using descriptive statistics. Item response modelling was used to inform a weighted scoring system. Reliability was assessed by internal consistency and test\u2013retest reliability; and validity by convergent and known-groups analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 80 adults enrolled, baseline data were available for 77 (96.3%) and 78 (97.5%) patients for the PKDD and PKDIA, respectively. Item responses skewed right, indicating that mean values exceeded median values, especially for items utilizing a 0\u201310 numeric scale, which were subsequently recoded to a 0\u20134 scale; 4 items were removed from the PKDIA due to redundancy or low relevance to the trial population. Both the PKDD and PKDIA demonstrated high internal consistency (McDonald\u2019s coefficient \u03c9\u2009=\u20090.86 and 0.90, respectively), test\u2013retest reliability (intra-class coefficients of 0.94 and 0.87, respectively), and convergent validity with other PROs (linear correlation coefficients [|r|] between 0.30\u20130.73 and 0.50\u20130.82, respectively).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The findings provide evidence of validity and reliability for the PKDD and PKDIA, the first disease-specific PRO measures for PK deficiency, and can therefore increase understanding of, and more accurately capture, the wider impact of PK deficiency on health-related quality of life.<\/jats:p>\n                    <jats:p>\n                      <jats:italic>Trial registration<\/jats:italic>\n                      ClinicalTrials.gov, NCT03548220. Registered June 07, 2018;\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03548220\">https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03548220<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41687-023-00650-3","type":"journal-article","created":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T11:02:59Z","timestamp":1699527779000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Psychometric validation of the Pyruvate Kinase Deficiency Diary and Pyruvate Kinase Deficiency Impact Assessment in adults in the phase 3 ACTIVATE trial"],"prefix":"10.1186","volume":"7","clinical-trial-number":[{"clinical-trial-number":"nct03548220","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"David A.","family":"Andrae","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael F.","family":"Grace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Jewett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Klaassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Salek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junlong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8342-173X","authenticated-orcid":false,"given":"Audra N.","family":"Boscoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Zagadailov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,9]]},"reference":[{"issue":"20","key":"650_CR1","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1182\/blood-2017-10-810796","volume":"131","author":"RF Grace","year":"2018","unstructured":"Grace RF, Bianchi P, van Beers EJ, Eber SW, Glader B, Yaish HM et al (2018) Clinical spectrum of pyruvate kinase deficiency: data from the pyruvate kinase deficiency natural history study. Blood 131(20):2183\u20132192","journal-title":"Blood"},{"issue":"2","key":"650_CR2","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.3324\/haematol.2018.196295","volume":"104","author":"EJ van Beers","year":"2019","unstructured":"van Beers EJ, van Straaten S, Morton DH, Barcellini W, Eber SW, Glader B et al (2019) Prevalence and management of iron overload in pyruvate kinase deficiency: report from the Pyruvate Kinase Deficiency Natural History Study. Haematologica 104(2):e51\u2013e53","journal-title":"Haematologica"},{"key":"650_CR3","doi-asserted-by":"publisher","first-page":"3513","DOI":"10.1182\/blood-2019-124381","volume":"134","author":"M Storm","year":"2019","unstructured":"Storm M, Secrest MH, Carrington C, Gilroy K, Pladson L, Boscoe AN et al (2019) Prevalence of red cell pyruvate kinase deficiency: a systematic literature review. Blood 134:3513","journal-title":"Blood"},{"issue":"1","key":"650_CR4","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/ajh.25325","volume":"94","author":"P Bianchi","year":"2019","unstructured":"Bianchi P, Fermo E, Glader B, Kanno H, Agarwal A, Barcellini W et al (2019) Addressing the diagnostic gaps in pyruvate kinase deficiency: Consensus recommendations on the diagnosis of pyruvate kinase deficiency. Am J Hematol 94(1):149\u2013161","journal-title":"Am J Hematol"},{"issue":"9","key":"650_CR5","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1002\/ajh.24088","volume":"90","author":"RF Grace","year":"2015","unstructured":"Grace RF, Zanella A, Neufeld EJ, Morton DH, Eber S, Yaish H et al (2015) Erythrocyte pyruvate kinase deficiency: 2015 status report. Am J Hematol 90(9):825\u2013830","journal-title":"Am J Hematol"},{"issue":"11","key":"650_CR6","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1182\/blood-2016-11-753525","volume":"130","author":"C Kung","year":"2017","unstructured":"Kung C, Hixon J, Kosinski PA, Cianchetta G, Histen G, Chen Y et al (2017) AG-348 enhances pyruvate kinase activity in red blood cells from patients with pyruvate kinase deficiency. Blood 130(11):1347\u20131356","journal-title":"Blood"},{"issue":"1","key":"650_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1365-2141.2005.05527.x","volume":"130","author":"A Zanella","year":"2005","unstructured":"Zanella A, Fermo E, Bianchi P, Valentini G (2005) Red cell pyruvate kinase deficiency: molecular and clinical aspects. Br J Haematol 130(1):11\u201325","journal-title":"Br J Haematol"},{"issue":"4","key":"650_CR8","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/ejh.13572","volume":"106","author":"AN Boscoe","year":"2021","unstructured":"Boscoe AN, Yan Y, Hedgeman E, van Beers EJ, Al-Samkari H, Barcellini W et al (2021) Comorbidities and complications in adults with pyruvate kinase deficiency. Eur J Haematol 106(4):484\u2013492","journal-title":"Eur J Haematol"},{"issue":"6","key":"650_CR9","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1111\/ejh.13128","volume":"101","author":"RF Grace","year":"2018","unstructured":"Grace RF, Cohen J, Egan S, Wells T, Witherspoon B, Ryan A et al (2018) The burden of disease in pyruvate kinase deficiency: patients\u2019 perception of the impact on health-related quality of life. Eur J Haematol 101(6):758\u2013765","journal-title":"Eur J Haematol"},{"issue":"6","key":"650_CR10","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1182\/bloodadvances.2021004675","volume":"6","author":"H Al-Samkari","year":"2022","unstructured":"Al-Samkari H, van Beers EJ, Morton DH, Eber SW, Chonat S, Kuo KHM et al (2022) Health-related quality of life and fatigue in children and adults with pyruvate kinase deficiency. Blood Adv 6(6):1844\u20131853","journal-title":"Blood Adv"},{"issue":"2","key":"650_CR11","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s11136-018-2025-y","volume":"28","author":"MS Salek","year":"2019","unstructured":"Salek MS, Ionova T, Johns JR, Oliva EN (2019) Appraisal of patient-reported outcome measures in analogous diseases and recommendations for use in phase II and III clinical trials of pyruvate kinase deficiency. Qual Life Res 28(2):399\u2013410","journal-title":"Qual Life Res"},{"issue":"5","key":"650_CR12","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1111\/ejh.13376","volume":"104","author":"S Salek","year":"2020","unstructured":"Salek S, Boscoe AN, Piantedosi S, Egan S, Evans CJ, Wells T et al (2020) Development of the Pyruvate Kinase Deficiency Diary and Pyruvate Kinase Deficiency Impact Assessment: disease-specific assessments. Eur J Haematol 104(5):427\u2013434","journal-title":"Eur J Haematol"},{"key":"650_CR13","unstructured":"US Food and Drug Administration (FDA) (2009) Guidance for industry on patient-reported outcome measures: use in medical product development to support labelling claims. https:\/\/www.fda.gov\/media\/77832\/download. Accessed 8 Mar 2023."},{"key":"650_CR14","unstructured":"US Food and Drug Administration (FDA) (2018) Patient-focused drug development guidance public workshop: methods to identify what is important to patients and select, develop or modify fit-for-purpose clinical outcomes assessments. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/patient-focused-drug-development-guidance-methods-identify-what-important-patients-and-select. Accessed 8 Mar 2023."},{"issue":"15","key":"650_CR15","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa2116634","volume":"386","author":"H Al-Samkari","year":"2022","unstructured":"Al-Samkari H, Galacteros F, Glenthoj A, Rothman JA, Andres O, Grace RF et al (2022) Mitapivat versus placebo for pyruvate kinase deficiency. N Engl J Med 386(15):1432\u20131442","journal-title":"N Engl J Med"},{"issue":"4","key":"650_CR16","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1037\/h0040957","volume":"52","author":"LJ Cronbach","year":"1955","unstructured":"Cronbach LJ, Meehl PE (1955) Construct validity in psychological tests. Psychol Bull 52(4):281\u2013302","journal-title":"Psychol Bull"},{"issue":"2","key":"650_CR17","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1037\/h0046016","volume":"56","author":"DT Campbell","year":"1959","unstructured":"Campbell DT, Fiske DW (1959) Convergent and discriminant validation by the multitrait-multimethod matrix. Psychol Bull 56(2):81\u2013105","journal-title":"Psychol Bull"},{"key":"650_CR18","unstructured":"Revelle W (2013) psych: procedures for psychological, psychometric, and personality research. R package version 1.0\u201395. Evanston, Illinois"},{"key":"650_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v048.i06","volume":"48","author":"R Chalmers","year":"2012","unstructured":"Chalmers R (2012) mirt: a multidimensional item response theory package for the R environment. J Stat Softw 48:1\u201329","journal-title":"J Stat Softw"},{"key":"650_CR20","unstructured":"R Core Team (2014) R: a language and environment for statistical computing [Software]. R Foundation for Statistical Computing, Vienna, Austria. Version 3.6.3 or higher"},{"issue":"1","key":"650_CR21","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jclinepi.2006.03.012","volume":"60","author":"CB Terwee","year":"2007","unstructured":"Terwee CB, Bot SD, de Boer MR, van der Windt DA, Knol DL, Dekker J et al (2007) Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol 60(1):34\u201342","journal-title":"J Clin Epidemiol"},{"issue":"8","key":"650_CR22","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.3899\/jrheum.110402","volume":"38","author":"J Fries","year":"2011","unstructured":"Fries J, Rose M, Krishnan E (2011) The PROMIS of better outcome assessment: responsiveness, floor and ceiling effects, and Internet administration. J Rheumatol 38(8):1759\u20131764","journal-title":"J Rheumatol"},{"issue":"3","key":"650_CR23","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1037\/1040-3590.7.3.309","volume":"7","author":"LA Clark","year":"1995","unstructured":"Clark LA, Watson D (1995) Constructing validity: basic issues in objective scale development. Psychol Assess 7(3):309\u2013319","journal-title":"Psychol Assess"},{"key":"650_CR24","unstructured":"Samejima F (2016) Graded response model. In: van der Linden WJ (ed) Handbook of modern item response theory, vol 1 Models, 1st edn. Boca Raton, FL, pp 95\u2013107"},{"key":"650_CR25","volume-title":"Factor analysis","author":"RL Gorsuch","year":"1983","unstructured":"Gorsuch RL (1983) Factor analysis, 2nd edn. Lawrence Erlbaum Associates Inc, Hillsdale, NJ","edition":"2"},{"issue":"6","key":"650_CR26","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1080\/00273171.2015.1032398","volume":"50","author":"S Monroe","year":"2015","unstructured":"Monroe S, Cai L (2015) Evaluating structural equation models for categorical outcomes: a new test statistic and a practical challenge of interpretation. Multivar Behav Res 50(6):569\u2013583","journal-title":"Multivar Behav Res"},{"issue":"1","key":"650_CR27","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1177\/014662169501900105","volume":"19","author":"D Thissen","year":"1995","unstructured":"Thissen D, Pommerich M, Billeaud K, Williams VSL (1995) Item response theory for scores on tests including polytomous items with ordered responses. Appl Psychol Meas 19(1):39\u201349","journal-title":"Appl Psychol Meas"},{"issue":"7","key":"650_CR28","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1007\/s11136-017-1527-3","volume":"26","author":"AL Gruber-Baldini","year":"2017","unstructured":"Gruber-Baldini AL, Velozo C, Romero S, Shulman LM (2017) Validation of the PROMIS(\u00ae) measures of self-efficacy for managing chronic conditions. Qual Life Res 26(7):1915\u20131924","journal-title":"Qual Life Res"},{"key":"650_CR29","volume-title":"Test theory: a unified approach","author":"RP McDonald","year":"1999","unstructured":"McDonald RP (1999) Test theory: a unified approach, 1st edn. Lawrence Erlbaum Associates Inc, Mahwah","edition":"1"},{"issue":"2","key":"650_CR30","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1037\/0033-2909.86.2.420","volume":"86","author":"PE Shrout","year":"1979","unstructured":"Shrout PE, Fleiss JL (1979) Intraclass correlations: uses in assessing rater reliability. Psychol Bull 86(2):420\u2013428","journal-title":"Psychol Bull"},{"key":"650_CR31","volume-title":"Statistical power analysis for the behavioural science","author":"J Cohen","year":"1988","unstructured":"Cohen J (1988) Statistical power analysis for the behavioural science, 2nd edn. Taylor & Francis Group","edition":"2"},{"key":"650_CR32","unstructured":"Agios Pharmaceuticals Inc. (2022) Pyrukynd (mitapivat) prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/216196s000lbl.pdf. Accessed 8 Mar 2023."},{"issue":"6","key":"650_CR33","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.3758\/s13428-020-01398-0","volume":"52","author":"D McNeish","year":"2020","unstructured":"McNeish D, Wolf MG (2020) Thinking twice about sum scores. Behav Res Methods 52(6):2287\u20132305","journal-title":"Behav Res Methods"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-023-00650-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-023-00650-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-023-00650-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T11:06:28Z","timestamp":1699527988000},"score":1,"resource":{"primary":{"URL":"https:\/\/jpro.springeropen.com\/articles\/10.1186\/s41687-023-00650-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,9]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["650"],"URL":"https:\/\/doi.org\/10.1186\/s41687-023-00650-3","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,9]]},"assertion":[{"value":"30 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Each subject was required to sign an informed consent form (ICF) to participate in the study. A legally authorized representative could have consented on behalf of a subject who was otherwise unable to provide informed consent, if acceptable to and approved by the site and\/or the site\u2019s institutional review board (IRB)\/independent ethics committee (IEC). An ICF that explained the procedures of the study, including the potential hazards, was reviewed and approved by the IRB\/IEC before its use. The ICF was read by and explained to each subject or their legally authorized representative before entering the study. Each subject had ample opportunity to ask questions and was assured of the right to withdraw from the study at any time without any disadvantage and without having to provide a reason for this decision. Each subject or representative received a signed and dated copy of the ICF. The study was conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"DAA is a former employee of Endpoint Outcomes and a current employee of BioMarin Pharmaceutical, Inc. RFG received research funding from Agios Pharmaceuticals Inc., Novartis, and\u00a0Sobi and consultancy from Agios Pharmaceuticals Inc., and Sanofi. RJK reports consultancy from Agios Pharmaceuticals Inc., Amgen, Biogen Canada Limited, Hoffman\u2010LaRoche Ltd, Novo Nordisk Canada Inc, Octapharma AG, Sanofi Genzyme, and Takeda Canada Inc. SS reports consultancy for Merck Healthcare KGaA and education grants from GlaxoSmithKline and The European Haematology Association. JL, FT, and\u00a0ANB are employees and shareholders of Agios Pharmaceuticals Inc. EZ is a former employee and shareholder of Agios Pharmaceuticals Inc. AJ and BF are employees of Endpoint Outcomes (now Lumanity).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"112"}}